NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
Open original source
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
Open original source